Servier Canada is a historical subsidiary of the renowned French pharmaceutical group, Servier, which has been operating in Canada since 1978. With over 45 years of experience, Servier Canada has established itself as a leader in cardiovascular and metabolic medicine. However, their commitment to innovation has led them to diversify into new areas, including oncology.

Under the guidance of their dedicated Executive Committee, Servier Canada aims to provide the Canadian medical community and its patients with groundbreaking therapeutic solutions. They collaborate with a wide range of stakeholders in the life sciences field, such as researchers, academic partners, clinicians, patient associations, and innovators. Servier is a privately-owned international pharmaceutical company driven by a non-profit organization.

This unique structure allows them to reinvest profits in research and maintain a patient-centric approach. Lucie Rousseau, Director of Operations for Servier Canada, envisions creating a sustainable and inclusive world while making a significant impact on the medical community and patients. Servier Canada's commitment to therapeutic progress and patient well-being remains unwavering, with a team of dedicated and passionate professionals who strive for a more just world